Taken together, these findings indicate that MEK/Bcl‐2 inhibition shows selectivity for CLL cells, and that early induction of apoptosis can predict sensitivity in 72‐h assays. This evidence concerns the gene MAP2K7 and B-cell chronic lymphocytic leukemia.